No Data
Reported Earlier, BeiGene Secures Global Licensing Agreement For Novel MAT2A Inhibitor SYH2039 To Target MTAP-Deleted Solid Tumors
Reported Earlier, BeiGene Highlights Long-Term BRUKINSA Efficacy And Pipeline Innovations For CLL At ASH 2024
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
BeiGene Started at Overweight at Morgan Stanley on Brukinsa Market Share Growth
Morgan Stanley Assumes BeiGene at Overweight, Announces Price Target of $300
Announcement - Distribution Announcement